Journal of Clinical Trials
Open Access

Abstract

Synthetically Treatments and Analyses, for Old Age Advanced Lung Adenocarcinoma

An-Tai He* and MPH Yi Pei

Purpose: To identify clinical treatment and feature of old age advanced lung adenocarcinoma. Using raised advanced lung adenocarcinoma clinical treatment level. Materials and Methods: Between January 2018-July 2018. 52 patients more than 60 old-years with advanced lung adenocarcinoma were divided 5 groups, with different treatment method. After all group patients were treated, compared survival rates. Results: Total group 52 patients survival rate, 1 years 88%, 2 years 70%, 3 years 38%, 4 years 34%, 5 years 23%. Median survival time 30 months. Surgical-operation-radiotherapy-chemical therapy-TKI therapy group survival rate: 1 years 100%, 2 years 100%, 3 years 57%, 4 years 35%, 5 years 35%, 6 years 21%. 10 years 14.2%, 15 years 7%, Median survival time 54 months. Chemical-TKI therapy group survival rate: 1 years 100%, 2 years 61%, 3 years 38%, 5 years 27%. Median survival time 28 months. Single TKI therapy group survival rate: 1 years 67%, 2 years 17%, Median survival time 14 months. Radiotherapy-chemical-TKI therapy group survival rate: 1 years 100%, 2 years 78%, 3 years 22%. Median survival time 29 months. Single chemical therapy group survival rate: 1 years 20%, Median survival time 8 months. Chemical-TKI therapy group compared single TKI therapy group u=0.28 p<0.01, α=0.05. ChemicalTKI therapy group compared radiotherapy-chemical-TKI therapy group p<0.1, α=0.05 without statistics meaning. Chemical-target-therapy group compared surgical operation-radio therapy-chemical-TKI therapy group 0.2

Received Date: 2022-03-14